Treatment of hyperlipidemic acute pancreatitis with plasma exchange: a single-center experience.
Of the cases of acute pancreatitis, 1-7% are caused by severe hypertriglyceridemia and can be treated with plasma exchange (PE). We report on a large series of patients with acute hyperlipidemic pancreatitis (HLP) treated with PE. In the 1992-2008 period, 50 patients (45 +/- 8 years old, 92% male) with acute HLP were treated with PE, during which 1-2 plasma volumes were exchanged. Heparin was used as anticoagulant in 85% of the procedures, and citrate in the rest. Cholesterol and triglycerides were measured before and after PE. In the 2003-2008 cohort of 40 patients, we retrospectively recorded an Acute Physiology and Chronic Health Evaluation II (APACHE II) score at the first PE session, hospital mortality, and length of hospital stay. A total of 79 PE treatments were done, 1-5 per patient. The volume exchanged was 4890 +/- 1300 mL over a duration of 3.5 +/- 2 h. During the first PE, the triglycerides were lowered from 58.9 +/- 40.8 to 10.8 +/- 10.8 mmol/L, and the total cholesterol was lowered from 20.0 +/- 7.6 to 5.7 +/- 4.3 mmol/L. In 10% of the procedures the plasmafilter was replaced, and in 3% the filter was clotted. Hypotension occurred in 3% of PE and there was one case of gastrointestinal bleeding after PE with heparin anticoagulation. In the 2003-2008 cohort, the median APACHE II score was 5 (range 0-15), the median overall hospital stay was 18 days (range 3-142 days) and the hospital mortality was 15%. To conclude, in acute hyperlipidemic pancreatitis, one to two plasma exchanges effectively reduce the serum triglyceride level. There is a low rate of procedure-related complications. A mortality rate of 15% is considerable.
Gubensek
Jakob
J
Department of Nephrology, University Medical Center Ljubljana, SI-1000 Ljubljana, Slovenia. jakob.gubensek@kclj.si
Buturović-Ponikvar
Jadranka
J
Marn-Pernat
Andreja
A
Kovac
Janko
J
Knap
Bojan
B
Premru
Vladimir
V
Ponikvar
Rafael
R
D000208:Acute Disease; D000328:Adult; D000368:Aged; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D002122:Calcium Chloride / Q000008:administration & dosage; D002784:Cholesterol / Q000097:blood; D002951:Citrates / Q000008:administration & dosage; D005260:Female; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects; D017052:Hospital Mortality; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications*; D007022:Hypotension / Q000209:etiology; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D010951:Plasma Exchange / Q000009:adverse effects / Q000379:methods*; D012189:Retrospective Studies; D014280:Triglycerides / Q000097:blood
D000925:Anticoagulants; D002951:Citrates; D014280:Triglycerides; C514290:trisodium citrate; D006493:Heparin; D002784:Cholesterol; D002122:Calcium Chloride